3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
12
Leukemia
8
Leukemia, Myeloid, Acute
7
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Congenital Abnormalities
2
Skin Neoplasms
1
Oropharyngeal Neoplasms
1
Neutropenia
1
Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Childhood Acute Promyelocytic Leukemia With PML-RARA
1
Carcinoma, Squamous Cell
1
Carcinoma, Basal Cell
1
Breast Cancer Female
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Olanzapine
4
Cyclophosphamide
4
Voriconazole
3
Tranexamic Acid
3
Standard of Care
3
nilotinib
2
letermovir
2
fludarabine phosphate
2
Zoledronic Acid
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methods
2
Imatinib Mesylate
2
Educational Status
2
Early Intervention, Educational
2
Doxorubicin
2
Cyclosporins
2
Cyclosporine
2
venetoclax
1
trihexyltetradecylphosphonium chloride
1
thymoglobulin
1
shengxuening
1
posaconazole
1
pembrolizumab
1
olaparib
1
maribavir
1
lenvatinib
1
ferrous succinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Neoplasms
×
Tretinoin
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled